CareDx, Inc. (CDNA) · Oct 29, 2026 · Earnings
Beat — Diluted GAAP EPS $0.35 vs approximately $0.25 consensus
CareDx earnings beat published Q3 expectations, while management sharply raised 2026 revenue and adjusted EBITDA guidance on stronger testing growth.
CareDx is expanding from a transplant-testing specialist into a broader precision-medicine platform spanning transplant, specialty oncology through NavDx, and cell therapy programs such as AlloHeme.
The quarter materially beat the market’s bar. Revenue reached $139.4 million versus published expectations around $122 million, while diluted GAAP EPS was $0.35 versus roughly $0.25 consensus. Testing Services drove the result, rising 65% year over year to $119 million, although $15 million came from prior-period revenue; excluding that item, growth was still approximately 58%.
| Metric | Q3 2026 | Q3 2025 | Consensus / Prior guide |
|---|---|---|---|
| Revenue (Financial tables) | $139.4M (+39%) | $100.1M | ~$122M consensus |
| Diluted GAAP EPS (Financial tables) | $0.35 | $0.03 | ~$0.25 consensus |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $30.5M (+99%) | $15.3M | — |
| FY2026 revenue guidance (Guidance) | $520–530M | — | $490–500M prior |
| FY2026 adjusted EBITDA guidance (Guidance) | $90–100M | — | $66–78M prior |
The bigger change is the guidance reset. CareDx lifted its full-year revenue range by $30 million at both ends and raised adjusted EBITDA guidance by $24 million at the low end and $22 million at the high end. That turns a strong quarter into evidence that the company sees the NavDx integration, transplant growth, and operating leverage carrying beyond one reporting period.
Profitability improved despite acquisition-related noise. Adjusted EBITDA margin expanded to 22% from 15% a year ago, and operating income turned positive at $8.1 million from a $0.2 million loss. The GAAP profit also benefited from an $8.6 million tax benefit, so adjusted EBITDA and the operating-line improvement are the cleaner read on underlying execution.
The pipeline now supports the growth story rather than merely promising it. AlloHeme is being advanced toward a planned first-quarter 2027 commercial launch, HistoMap Kidney is targeted for broader 2027 availability, and NavDx evidence is expanding across treatment and surveillance settings. Those are future opportunities, but this filing shows the existing commercial portfolio is already scaling profitably. 〔0〕
Bottom line: This is more than an in-line growth quarter: CareDx beat expectations and raised the full-year outlook substantially. The filing strengthens the case that oncology expansion and transplant execution are becoming a durable, higher-profit growth engine, not just an acquisition story.
AlloHeme CLIA readiness and planned Q1 2027 launch
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!